Search Result

Results for "

5-HT Receptor Agonists

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (286) Adenylate Cyclase (1) Adrenergic Receptor (42) Androgen Receptor (1) Apoptosis (8) Autophagy (6) Cannabinoid Receptor (1) Cytochrome P450 (1) Dopamine Receptor (64) Drug Metabolite (5) Endogenous Metabolite (6) GABA Receptor (2) Histamine Receptor (5) Isotope-Labeled Compounds (21) mAChR (6) Melatonin Receptor (8) Monoamine Oxidase (1) nAChR (10) P2X Receptor (1) Parasite (2) Phosphatase (1) Potassium Channel (4) Reactive Oxygen Species (4) Renin (3) Serotonin Transporter (10) Sigma Receptor (4) Sodium Channel (5) Trk Receptor (4) TRP Channel (1)
By Research Areas:	Cancer (23) Cardiovascular Disease (12) Endocrinology (21) Infection (4) Inflammation/Immunology (16) Metabolic Disease (20) Neurological Disease (259)

By Targets:

5-HT Receptor (286)

Adenylate Cyclase (1)

Adrenergic Receptor (42)

Androgen Receptor (1)

Apoptosis (8)

Autophagy (6)

Cannabinoid Receptor (1)

Cytochrome P450 (1)

Dopamine Receptor (64)

Drug Metabolite (5)

Endogenous Metabolite (6)

GABA Receptor (2)

Histamine Receptor (5)

Isotope-Labeled Compounds (21)

mAChR (6)

Melatonin Receptor (8)

Monoamine Oxidase (1)

nAChR (10)

P2X Receptor (1)

Parasite (2)

Phosphatase (1)

Potassium Channel (4)

Reactive Oxygen Species (4)

Renin (3)

Serotonin Transporter (10)

Sigma Receptor (4)

Sodium Channel (5)

Trk Receptor (4)

TRP Channel (1)

By Research Areas:

Cancer (23)

Cardiovascular Disease (12)

Endocrinology (21)

Infection (4)

Inflammation/Immunology (16)

Metabolic Disease (20)

Neurological Disease (259)

301

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: 5-HT Receptor

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-G0014A

Quetiapine sulfoxide dihydrochloride Quetiapine S-oxide dihydrochloride	Drug Metabolite	Neurological Disease
Quetiapine sulfoxide dihydrochloride (Quetiapine S-oxide dihydrochloride) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic . Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist .

HY-W335976

Almotriptan hydrochloride	5-HT Receptor	Cancer
Almotriptan hydrochloride is a selective agonist of **5-HT 1B/1D Receptor**. Almotriptan hydrochloride can used in study of migraine attacks .

HY-119806

TMPPAA

5-HT Receptor Neurological Disease

TMPPAA is an allosteric agonist and positive allosteric modulator of the 5-HT3 receptor. TMPPAA enhances 5-HT-mediated 5-HT3AR signaling .

TMPPAA	5-HT Receptor	Neurological Disease
TMPPAA is an allosteric agonist and positive allosteric modulator of the *5-HT3* receptor. TMPPAA enhances *5-HT*-mediated 5-HT3AR signaling .

HY-101630A

Deramciclane fumarate EGIS-3886 fumarate	5-HT Receptor	Others
Deramciclane fumarate is an antagonist of **5-HT Receptor*. Deramciclane fumarate is an inverse agonist* of **5-HT_2C Receptor with an IC₅₀** of 168 nM. Deramciclane fumarate also decreases basal phosphoinositide hydrolysis .

HY-B0031S

Quetiapine-d4 fumarate	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine-d₄ (fumarate) is the deuterium labeled Quetiapine fumarate. Quetiapine fumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects[1].

HY-G0014B

Quetiapine sulfoxide hydrochloride Quetiapine S-oxide hydrochloride	Drug Metabolite	Neurological Disease
Quetiapine sulfoxide hydrochloride (Quetiapine S-oxide hydrochloride) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic . Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist .

HY-G0014

Quetiapine sulfoxide Quetiapine S-oxide	Drug Metabolite	Neurological Disease
Quetiapine sulfoxide (Quetiapine S-oxide) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic . Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist .

HY-113008A

cis-Urocanic acid (Z)-Urocanic acid; cis-UCA	5-HT Receptor	Inflammation/Immunology
cis-Urocanic acid is a **5-HT2A receptor** agonist. cis-Urocanic acid binds to **5-HT receptor with relatively high affinity (K_d*=4.6 nM). cis-Urocanic acid is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor* .

HY-14557A

Pimavanserin hemitartrate 10+ Cited Publications ACP-103 hemitartrate	5-HT Receptor	Neurological Disease
Pimavanserin (ACP-103) hemitartrate is a potent 5-HT 2A receptor inverse agonist with pIC₅₀ and pK_i of 8.73 and 9.3, respectively.

HY-B0031S1

Quetiapine-d4 hemifumarate	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine-d₄ (hemifumarate) is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects[1].

HY-B0383A

Almotriptan

5-HT Receptor Neurological Disease

Almotriptan is a selective agonist of 5-HT 1B/1D Receptor. Almotriptan can used in study of migraine attacks .

Almotriptan	5-HT Receptor	Neurological Disease
Almotriptan is a selective agonist of **5-HT 1B/1D Receptor**. Almotriptan can used in study of migraine attacks .

HY-118008A

Lesopitron hydrochloride	5-HT Receptor	Neurological Disease
Lesopitron hydrochloride is a **5-HT receptor** agonist with potent anxiolytic-like effects. Lesopitron hydrochloride inhibits forskolin-stimulated adenylate cyclase activity with an IC₅₀ value of 125 nM .

HY-13221

BRL 54443	5-HT Receptor	Cardiovascular Disease
BRL 54443 is a potent *5-HT_1E/1F* receptor agonist (K_i values are 1.1 nM and 0.7 nM respectively); displays > 30-fold selectivity over other 5-HT and dopamine receptors .

HY-124501

LY 165163 p-NH2-PE-TFMPP	5-HT Receptor	Neurological Disease
LY 165163 is a potent **5-HT presynaptic receptor** agonist. LY 165163 significantly decreases 5-HTP accumulation and increases DOPA accumulation in the cortex and striatum .

HY-118008

Lesopitron	5-HT Receptor	Neurological Disease
Lesopitron (E-4424) is a **5-HT receptor** agonist with potent anxiolytic-like effects. Lesopitron inhibits forskolin-stimulated adenylate cyclase activity with an IC₅₀ value of 125 nM .

HY-113008AS

cis-Urocanic acid-13C3 (Z)-Urocanic acid-¹³C₃; cis-UCA-¹³C₃	Isotope-Labeled Compounds 5-HT Receptor	Inflammation/Immunology
cis-Urocanic acid- ¹³C₃ is the ¹³C-labeled cis-Urocanic acid. cis-Urocanic acid is a 5-HT2A receptor agonist. cis-Urocanic acid binds to 5-HT receptor with relatively high affinity (Kd=4.6 nM). cis-Urocanic acid is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor[1].

HY-123704

CGS-12066 maleate	5-HT Receptor	Neurological Disease
CGS-12066 (maleate) is a 5-HT receptor agonist. CGS-12066 has agonist effect for 5-HT_1A , 5-HT_1B ,5-HT_1C and 5-HT_1D with pEC₅₀ values of 6.41, 7.56, 4.05 and 7.11, respectively. CGS-12066 can be used for the research of neurological disease .

HY-116594A

OPC-14523 hydrochloride	Sigma Receptor 5-HT Receptor	Neurological Disease
OPC-14523 hydrochloride is an orally active sigma and **5-HT1A receptor** agonist, with high affinity for sigma receptors (σ1/2 IC₅₀=47/56 nM), the 5-HT1A receptor (IC₅₀=2.3 nM), and the 5-HT transporter (IC₅₀=80 nM). OPC-14523 hydrochloride shows antidepressant-like activity .

HY-B0031

Quetiapine hemifumarate 1 Publications Verification	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine hemifumarate is a **5-HT receptors** agonist with a pEC₅₀ of 4.77 for human **5-HT1A receptor*. Quetiapine hemifumarate is a dopamine receptor* antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, *5-HT2A, *5-HT2C receptor with pK_i**s of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-14544

Quetiapine 1 Publications Verification ICI204636	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine (ICI204636) is a **5-HT receptors** agonist with a pEC₅₀ of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, *5-HT2A, *5-HT2C receptor with pK_i**s of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-16688A

RU 24969 succinate 1 Publications Verification	5-HT Receptor	Neurological Disease
RU 24969 succinate is a *5-HT* receptor agonist with K_i values of 0.38 and 2.5 nM for 5-HT_1B and 5-HT_1A, respectively. RU 24969 decreases fluid consumption and increases forward locomotion. RU 24969 succinate can be used for the research of neurological disease .

HY-G0014S

Quetiapine Sulfoxide-d8	Isotope-Labeled Compounds Drug Metabolite	Neurological Disease
Quetiapine Sulfoxide-d₈ is the deuterium labeled Quetiapine sulfoxide. Quetiapine sulfoxide (Quetiapine S-oxide) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic[1]. Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist[1][2].

HY-116594

OPC-14523 free base	Sigma Receptor 5-HT Receptor	Neurological Disease
OPC-14523 free base is an orally active sigma and **5-HT1A receptor** agonist, with high affinity for sigma receptors (σ1/2 IC₅₀=47/56 nM), the 5-HT1A receptor (IC₅₀=2.3 nM), and the 5-HT transporter (IC₅₀=80 nM). OPC-14523 free base shows antidepressant-like activity .

HY-B0383AS2

Almotriptan-d3 benzoate	5-HT Receptor Isotope-Labeled Compounds	Neurological Disease
Almotriptan-d₃ benzoate is deuterated labeled Almotriptan (HY-B0383A). Almotriptan is a selective agonist of **5-HT 1B/1D Receptor**. Almotriptan can used in study of migraine attacks .

HY-B0031S2

Quetiapine-d8 fumarate	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine-d₈ (fumarate) is the deuterium labeled Quetiapine. Quetiapine is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1][2].

HY-14544R

Quetiapine (Standard)	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine (Standard) is the analytical standard of Quetiapine. This product is intended for research and analytical applications. Quetiapine (ICI204636) is a **5-HT receptors** agonist with a pEC₅₀ of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, *5-HT2A, *5-HT2C receptor with pK_i**s of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-B0031S3

Quetiapine-d8 hemifumarate	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine-d₈ (hemifumarate) is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].

HY-B0031S4

Quetiapine hemifumarate-d8	Dopamine Receptor 5-HT Receptor	Neurological Disease
Quetiapine (hemifumarate)-d₈ is the deuterium labeled Quetiapine hemifumarate[1]. Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[2].

HY-B0031R

Quetiapine hemifumarate (Standard)	5-HT Receptor Dopamine Receptor	Neurological Disease
Quetiapine (hemifumarate) (Standard) is the analytical standard of Quetiapine (hemifumarate). This product is intended for research and analytical applications. Quetiapine hemifumarate is a **5-HT receptors** agonist with a pEC₅₀ of 4.77 for human **5-HT1A receptor*. Quetiapine hemifumarate is a dopamine receptor* antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, *5-HT2A, *5-HT2C receptor with pK_i**s of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-B0031S5

Quetiapine-d4-1 fumarate	Dopamine Receptor 5-HT Receptor Isotope-Labeled Compounds	Neurological Disease
Quetiapine-d₄-1 fumarate is deuterated labeled Quetiapine (hemifumarate) (HY-B0031). Quetiapine hemifumarate is a **5-HT receptors** agonist with a pEC₅₀ of 4.77 for human **5-HT1A receptor*. Quetiapine hemifumarate is a dopamine receptor* antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, *5-HT2A, *5-HT2C receptor with pK_i**s of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-160921

Capeserod SL65.0155 free base	5-HT Receptor	Neurological Disease
Capeserod (SL65.0155 free base) is an agonist for serotonin receptor (5-HT *receptor), with a K_i of 0.6 nM for 5-HT₄* receptor. Capeserod enhances expression of phopshorilated cAMP-response element binding protein (p-CREB), vascular endothelium growth factor (VEGF), brain-derived neurotrophic factor (BDNF) and B cell lymphoma-2 (Bcl-2) proteins in hippocampus, and exhibits antidepressant-like efficacy in Wistar rats models .

HY-153091

BMY 14802	Adrenergic Receptor 5-HT Receptor Sigma Receptor	Neurological Disease
BMY 14802 is a sigma-1 receptor (σ1R) antagonist, as well as an agonist at *serotonin (5-HT) 1A* and adrenergic alpha-1 receptors. BMY 14802 inhibits abnormal involuntary movement (AIM) in rat Parkinson's disease (PD) model, with down-regulating the expression of AIM .

HY-109112

Brilaroxazine RP5063	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-100769

Hypidone hydrochloride 1 Publications Verification YL0919	5-HT Receptor	Neurological Disease
Hypidone hydrochloride (YL0919) is an orally active antidepressant agent with dual activity as a highly seletive 5-HT uptake blocker and an effective *5-HT_1A receptor* agonist (K_i=0.19 nM). Hypidone hydrochloride inhibits the uptake of [ ³H]-5-HT into rat cerebral cortical synaptosomes and HEK293 cells with IC₅₀s of 1.78 nM and 1.93 nM, respectively. Hypidone hydrochloride shows remarkable antidepressant effects in animal models and has the poential for the investigation of depressive disorder .

HY-109112R

Brilaroxazine (Standard)	Dopamine Receptor 5-HT Receptor	Neurological Disease Inflammation/Immunology
Brilaroxazine (Standard) is the analytical standard of Brilaroxazine. This product is intended for research and analytical applications. Brilaroxazine (RP5603) is a potent and orally active multimodal dopamine (DA)/serotonin (5-HT) modulator. Brilaroxazine is a partial agonist of dopamine (DA) D2, D3, and D4 receptors, 5-HT1A (K_i=1.5 nM) and 5-HT2A (K_i=2.5 nM), and has antagonist activity at 5-HT2B (K_i=0.19 nM), and 5-HT7 (K_i=2.7 nM) receptors . Brilaroxazine is an atypical antipsychotic agent, and has the potential to improve cognitive impairments in neuropsychiatric and neurological diseases in vivo .

HY-14151

Prucalopride 2 Publications Verification	5-HT Receptor Apoptosis Autophagy	Neurological Disease Cancer
Prucalopride is an orally active, selective and specific **5-HT 4 receptor** agonist (high affinity), with pK_is of 8.6 and 8.1 for human **5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor** signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-B0527A

Amitriptyline hydrochloride 3 Publications Verification	Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Sodium Channel Trk Receptor	Neurological Disease Cancer
Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and **5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB** receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity .

HY-B1658A

Frovatriptan succinate hydrate (R)-Frovatriptan succinate hydrate; SB 209509 succinate hydrate; VML 251 succinate hydrate	5-HT Receptor	Neurological Disease
Frovatriptan succinate hydrate ((R)-Frovatriptan succinate hydrate) is a potent, high affinity, selective and orally active *5-HT_1B* (pK₅₀ of 8.2) and **5-HT_1D receptor** agonist. Frovatriptan succinate hydrate exhibits >10-fold selectivity for *5-HT_1B* and *5-HT_1D* over 5-HT_1A, 5-HT_1F, and 5-HT₇ and >1000-fold selectivity over other 5-HT, dopamine, histamine H₁, and α1-adrenoceptor. Frovatriptan succinate hydrate has the potential for migraine research .

HY-B1658B

Frovatriptan succinate (R)-Frovatriptan succinate; SB 209509 succinate; VML 251 succinate	5-HT Receptor	Neurological Disease
Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active *5-HT_1B* (pK₅₀ of 8.2) and **5-HT_1D receptor** agonist. Frovatriptan succinate exhibits >10-fold selectivity for *5-HT_1B* and *5-HT_1D* over 5-HT_1A, 5-HT_1F, and 5-HT₇ and >1000-fold selectivity over other 5-HT, dopamine, histamine H₁, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research .

HY-12694

Prucalopride succinate 2 Publications Verification R-108512	5-HT Receptor Apoptosis Autophagy	Metabolic Disease Cancer
Prucalopride succinate is an orally active, selective and specific **5-HT 4 receptor** agonist (high affinity), with pK_is of 8.6 and 8.1 for human **5-HT4a/4b receptors, respectively. Prucalopride succinate improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride succinate also shows anticancer activity by blocking of the PI3K/AKT/mTor** signaling pathway. Prucalopride succinate can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-B1658BS

Frovatriptan-d3 succinate (R)-Frovatriptan-d₃ succinate; SB 209509-d₃ succinate; VML 251-d₃ succinate	Isotope-Labeled Compounds 5-HT Receptor	Neurological Disease
Frovatriptan-d₃ (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research[1][2].

HY-B0527AS

Amitriptyline-d6 hydrochloride	Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Sodium Channel Trk Receptor	Neurological Disease
Amitriptyline-d₆ (hydrochloride) is the deuterium labeled Amitriptyline hydrochloride. Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with Kis of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a Ki of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity[1][2][3].

HY-135096

Amitriptyline-d3 hydrochloride	Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Sodium Channel Trk Receptor	Neurological Disease
Amitriptyline-d3 hydrochloride is the deuterium labeled Amitriptyline (hydrochloride). Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and **5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB** receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity .

HY-145841

5-HT2A receptor agonist-2	5-HT Receptor	Cardiovascular Disease
5-HT2A receptor agonist-2 is a highly potent serotonin **5-HT2 receptor** agonists. 5-HT2A receptor agonist-2 inspires 5-HT_2A, 5-HT_2B, and 5-HT_2C with EC₅₀ values of 1.7, 0.58, and 0.50 nM, respectively .

HY-14151R

Prucalopride (Standard)	5-HT Receptor Apoptosis Autophagy	Neurological Disease Cancer
Prucalopride (Standard) is the analytical standard of Prucalopride. This product is intended for research and analytical applications. Prucalopride is an orally active, selective and specific **5-HT 4 receptor** agonist (high affinity), with pK_is of 8.6 and 8.1 for human **5-HT4a/4b receptors, respectively. Prucalopride improves intestinal motility by promoting regeneration of the intestinal nervous system in rats. Prucalopride also shows anticancer activity by blocking of the PI3K/AKT/mTor** signaling pathway. Prucalopride can be used in studies of chronic constipation, pseudo-intestinal obstruction and cancer .

HY-153912

5-HT2A receptor agonist-3	5-HT Receptor	Others
5-HT2A receptor agonist-3 is the most selective agonist for the human **5-HT2A receptor yet discovered, with a K_i of 2.5 nM, and with 124-fold selectivity for 5-HT2A over the structurally similar 5-HT2C receptor** .

HY-B0527AR

Amitriptyline hydrochloride (Standard)	Serotonin Transporter 5-HT Receptor Histamine Receptor mAChR Adrenergic Receptor Sodium Channel Trk Receptor	Neurological Disease Cancer
Amitriptyline (hydrochloride) (Standard) is the analytical standard of Amitriptyline (hydrochloride). This product is intended for research and analytical applications. Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with K_is of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a K_i of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and **5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB** receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity .

HY-109527

5-HT7 agonist 1	5-HT Receptor	Neurological Disease
5-HT7 agonist 1 is a selective **5-HT7 receptor** agonist, with an IC₅₀ of 222.93 nM, can be used for the 5-HT7 receptor related disease, such as CNS disorders.

HY-101630

Deramciclane EGIS-3886	5-HT Receptor	Neurological Disease
Deramciclane has a high affinity for *5-HT_2A* and *5-HT_2C* receptors; it acts as an antagonist at both receptor subtypes and has inverse agonist properties at the 5-HT_2C receptors without direct stimulatory agonist.

HY-147399

5-HT7 agonist 2	5-HT Receptor	Neurological Disease
5-HT7 agonist 2 is a potent **5-HT₇ receptor** agonist with an IC₅₀ value of 28.7 nM. 5-HT7 agonist 2 can be used for research of central nervous system (CNS) disorders .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0049

Nuciferine 4 Publications Verification	Structural Classification Alkaloids Aporphine Alkaloids other families Source classification Plants Isoquinoline Alkaloids	Parasite 5-HT Receptor Dopamine Receptor
Nuciferine is an antagonist at *5-HT_2A* (IC₅₀=478 nM), *5-HT_2C* (IC₅₀=131 nM), and *5-HT_2B* (IC₅₀=1 μM), an inverse agonist at *5-HT₇* (IC₅₀=150 nM), a partial agonist at D₂ (EC₅₀=64 nM), D₅ (EC₅₀=2.6 μM) and *5-HT₆* (EC₅₀=700 nM), an agonist at *5-HT_1A* (EC₅₀=3.2 μM) and D₄ (EC₅₀=2 μM) receptor.

HY-N2411

Geissoschizine methyl ether	Uncaria rhynchophylla (Miq.) Miq. ex Havil. Alkaloids Structural Classification Source classification Rubiaceae Plants Indole Alkaloids	5-HT Receptor
Geissoschizine methyl ether, a major indole alkaloid found in Uncaria hook, is a major active component of Yokukansan with psychotropic effects. Geissoschizine methyl ether is potent **5-HT_1A receptor** agonist .

HY-17038

Agomelatine 3 Publications Verification S-20098	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective **5-HT2C receptor antagonist with pK_i*s of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors*, respectively .

HY-N3398

Lauroscholtzine N-Methyllaurotetanine	Structural Classification Alkaloids Thalictrum revolutum DC. Source classification Ranunculaceae Plants Isoquinoline Alkaloids	5-HT Receptor
Lauroscholtzine (N-Methyllaurotetanine), a natural alkaloid, is a **5-HT1A receptor** agonist .

HY-N0049R

Nuciferine (Standard)	Structural Classification Alkaloids other families Source classification Plants	5-HT Receptor Dopamine Receptor
Nuciferine (Standard) is the analytical standard of Nuciferine. This product is intended for research and analytical applications. Nuciferine is an antagonist at *5-HT_2A* (IC₅₀=478 nM), *5-HT_2C* (IC₅₀=131 nM), and *5-HT_2B* (IC₅₀=1 μM), an inverse agonist at *5-HT₇* (IC₅₀=150 nM), a partial agonist at D₂ (EC₅₀=64 nM), D₅ (EC₅₀=2.6 μM) and *5-HT₆* (EC₅₀=700 nM), an agonist at *5-HT_1A* (EC₅₀=3.2 μM) and D₄ (EC₅₀=2 μM) receptor.

HY-17038A

Agomelatine hydrochloride 3 Publications Verification S-20098 hydrochloride	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine hydrochloride (S-20098 hydrochloride) is a specific agonist of MT1 and MT2 receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine hydrochloride is a selective **5-HT2C receptor antagonist with pK_i*s of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors*, respectively .

HY-N8200

Cassiaside B2	Monophenols Classification of Application Fields Cassia obtusifolia L. Source classification Phenols Caesalpiniaceae Plants Disease Research Fields Inflammation/Immunology	Phosphatase Monoamine Oxidase 5-HT Receptor
Cassiaside B2 is a protein tyrosine phosphatase 1B (PTP1B) and human monoamine oxidase A (hMAO-A) inhibitor. Cassiaside B2 possesses antiallergic and is a *5-HT2C* receptor agonist . ..

HY-17038B

Agomelatine (L(+)-Tartaric acid) 3 Publications Verification S-20098 L(+)-Tartaric acid	Structural Classification Alkaloids Neurological Disease Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine L(+)-Tartaric acid (S-20098 L(+)-Tartaric acid) is a specific agonist of MT1 and MT2 receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine L(+)-Tartaric acid is a selective **5-HT2C receptor antagonist with pK_i*s of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors*, respectively .

HY-17038R

Agomelatine (Standard)	Structural Classification Alkaloids Other Alkaloids Source classification Endogenous metabolite	Melatonin Receptor 5-HT Receptor Endogenous Metabolite
Agomelatine (Standard) is the analytical standard of Agomelatine. This product is intended for research and analytical applications. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with K_is of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively . Agomelatine is a selective **5-HT2C receptor antagonist with pK_i*s of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors*, respectively .

Cat. No.	Product Name	Chemical Structure

HY-B0031S1

Quetiapine-d4 hemifumarate
Quetiapine-d₄ (hemifumarate) is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects[1].

HY-113008AS

cis-Urocanic acid-13C3
cis-Urocanic acid- ¹³C₃ is the ¹³C-labeled cis-Urocanic acid. cis-Urocanic acid is a 5-HT2A receptor agonist. cis-Urocanic acid binds to 5-HT receptor with relatively high affinity (Kd=4.6 nM). cis-Urocanic acid is an immune modulator that induces immunosuppression by binding to the 5-HT2A receptor[1].

HY-B0031S

Quetiapine-d4 fumarate
Quetiapine-d₄ (fumarate) is the deuterium labeled Quetiapine fumarate. Quetiapine fumarate is a 5-HT receptors agonist and a dopamine receptor antagonist. Antidepressant and anxiolytic effects[1].

HY-G0014S

Quetiapine Sulfoxide-d8
Quetiapine Sulfoxide-d₈ is the deuterium labeled Quetiapine sulfoxide. Quetiapine sulfoxide (Quetiapine S-oxide) is a main metabolite of Quetiapinem. Quetiapine is a second-generation antipsychotic[1]. Quetiapine is a 5-HT receptors agonist and a dopamine receptor antagonist[1][2].

HY-B0383AS2

Almotriptan-d3 benzoate
Almotriptan-d₃ benzoate is deuterated labeled Almotriptan (HY-B0383A). Almotriptan is a selective agonist of **5-HT 1B/1D Receptor**. Almotriptan can used in study of migraine attacks .

HY-B0031S2

Quetiapine-d8 fumarate

Quetiapine-d₈ (fumarate) is the deuterium labeled Quetiapine. Quetiapine is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1][2].

HY-B0031S3

Quetiapine-d8 hemifumarate

Quetiapine-d₈ (hemifumarate) is the deuterium labeled Quetiapine hemifumarate. Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[1].

HY-B0031S4

Quetiapine hemifumarate-d8

Quetiapine (hemifumarate)-d₈ is the deuterium labeled Quetiapine hemifumarate[1]. Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pKis of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects[2].

HY-B0031S5

Quetiapine-d4-1 fumarate

Quetiapine-d₄-1 fumarate is deuterated labeled Quetiapine (hemifumarate) (HY-B0031). Quetiapine hemifumarate is a 5-HT receptors agonist with a pEC₅₀ of 4.77 for human 5-HT1A receptor. Quetiapine hemifumarate is a dopamine receptor antagonist with a pIC₅₀ of 6.33 for human D2 receptor. Quetiapine hemifumarate has moderate to high affinity for the human D2, HT1A, 5-HT2A, 5-HT2C receptor with pK_is of 7.25, 5.74, 7.54, 5.55. Antidepressant and anxiolytic effects .

HY-B1658BS

Frovatriptan-d3 succinate

Frovatriptan-d₃ (succinate) is deuterium labeled Frovatriptan (succinate). Frovatriptan succinate ((R)-Frovatriptan succinate) is a potent, high affinity, selective and orally active 5-HT1B (pK50 of 8.2) and 5-HT1D receptor agonist. Frovatriptan succinate exhibits >10-fold selectivity for 5-HT1B and 5-HT1D over 5-HT1A, 5-HT1F, and 5-HT7 and >1000-fold selectivity over other 5-HT, dopamine, histamine H1, and α1-adrenoceptor. Frovatriptan succinate has the potential for migraine research[1][2].

HY-B0527AS

Amitriptyline-d6 hydrochloride

Amitriptyline-d₆ (hydrochloride) is the deuterium labeled Amitriptyline hydrochloride. Amitriptyline hydrochloride is an inhibitor of serotonin reuptake transporter (SERT) and noradrenaline reuptake transporter (NET), with Kis of 3.45 nM and 13.3 nM for human SERT and NET, respectively. Amitriptyline hydrochloride also weakly binds to dopamine reuptake transporter (DAT) with a Ki of 2.58 μM. Amitriptyline hydrochloride also inhibits adrenergic, muscarinic, histamine and 5-HT receptors. Amitriptyline hydrochloride is a TrkA and TrkB receptors agonist with potent neurotrophic activity. Amitriptyline hydrochloride has antidepressant activity[1][2][3].

HY-B0197S

Naratriptan-d3

Naratriptan-d₃ is the deuterium labeled Naratriptan[1]. Naratriptan is a selective 5-HT1 receptor subtype agonist[2].
HY-B0197AS

Naratriptan-d3 hydrochloride

Naratriptan-d₃ (hydrochloride) is the deuterium labeled Naratriptan, which is a selective 5-HT1 receptor subtype agonist.
HY-B0716S2

Urapidil-d4

Urapidil-d₄ is the deuterium labeled Urapidil[1]. Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist[2].

HY-B0121BS

Sumatriptan-d6 succinate
Sumatriptan-d6 succinate is the deuterium labeled Sumatriptan succinate. Sumatriptan succinate is an orally active **5-HT1 receptor** agonist with K_is of 17 nM, 27 nM and 100 nM for *5-HT1D, 5-HT1B* and **5-HT1A receptors**, respectively. Sumatriptan succinate can be used for migraine headache research .

HY-14546S

Aripiprazole-d8

Aripiprazole-d₈ is the deuterium labeled Aripiprazole, which is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM.
HY-B0716S1

Urapidil-d3

Urapidil-d₃ is the deuterium labeled Urapidil. Urapidil is an α1 adrenoreceptor antagonist and a 5-HT1A receptor agonist.

HY-14153AS

Tegaserod-13C,d3 maleate
Tegaserod- ¹³C,d₃ (maleate) is the ¹³C- and deuterium labeled Tegaserod (maleate). Tegaserod maleate is a selective 5-HT4 receptor partial agonist and a 5-HT2B receptor antagonist. Tegaserod maleate exhibits a promotile effect throughout the gastrointestinal (GI) tract[1][2][5].

HY-A0039S

Eletriptan-d3
Eletriptan-d₃ is the deuterium labeled Eletriptan hydrobromide. Eletriptan hydrobromide is a selective 5-HT1B and 5-HT1D receptor agonist with Ki of 0.92 nM and 3.14 nM, respectively[1][2].

HY-A0095S

Flibanserin-d4
Flibanserin-d₄ is a deuterium labeled Flibanserin (BIMT-17). Flibanserin is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM)[1].

HY-14261S

Vilazodone-d8

Vilazodone-d₈ is the a deuterium labeled vilazodone, which is a combined serotonin specific reuptake inhibitor (SSRI) and 5-HT1A receptor partial agonist.

HY-32329S

Setiptiline-d3

Setiptiline-d₃ is the deuterium labeled Setiptiline. Setiptiline (Org-8282) is a serotonin receptor antagonist. Setiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). Setiptiline acts as a norepinephrine reuptake inhibitor, α2-adrenergic receptor antagonist, and serotonin receptor antagonist, likely at the 5-HT2A, 5-HT2C, and/or 5-HT3 subtypes, as well as an H1 receptor inverse agonist/antihistamine[1][2].

HY-B0121BS2

Sumatriptan-d5
Sumatriptan-d₅ is deuterated labeled Sumatriptan (HY-B0121B). Sumatriptan (GR 43175) is an orally active **5-HT1 receptor** agonist with IC₅₀s of 7.3 nm, 9.3nm and 17.8 nm for 5-HT_1D, 5-HT_1B and 5-HT_1F receptors, respectively. Sumatriptan can be used for migraine headache research .

HY-15780S

Brexpiprazole-d8
Brexpiprazole-d₈ is a deuterium labeled Brexpiprazole (OPC-34712). Brexpiprazole, an atypical antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine receptor (Ki=0.12 nM and 0.3 nM, respectively). Brexpiprazole is also a 5-HT2A receptor antagonist (Ki=0.47 nM)[1][2].

HY-14153S

Tegaserod-d11

Tegaserod-d₁₁ is deuterated labeled Tegaserod (HY-14153). Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT₄R) agonist and a 5-HT_2B receptor antagonist. Tegaserod has pK_is of 7.5, 8.4 and 7.0 for human recombinant 5-HT_2A, 5-HT_2B and 5-HT_2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research .

HY-A0095S1

Flibanserin-d4-1

Flibanserin-d₄-1 is deuterium labeled Flibanserin. Flibanserin (BIMT-17) is a full agonist of the serotonin 5-HT1A receptor (Ki=1 nM) and an antagonist of 5-HT2A (49 nM). Flibanserin binds to dopamine D4 receptors (4-24 nM), and has negligible affinity for a variety of other neurotransmitter receptors and ion channels. Flibanserin is efficacious in treating hypoactive sexual desire disorder (HSDD)[1][2].

HY-15394S

(Rac)-Rotigotine-d7 hydrochloride

(Rac)-Rotigotine-d₇ (hydrochloride) is deuterium labeled (Rac)-Rotigotine (hydrochloride). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of dopamine receptor, a partial agonist of the 5-HT1A receptor, and an antagonist of the α2B-adrenergic receptor, with Kis of 0.71 nM, 4-15 nM, and 83 nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-B0032AS

Lurasidone-d8
Lurasidone-d₈ is deuterium labeled Lurasidone. Lurasidone (SM-13496) is an antagonist of both dopamine D2 and 5-HT7 with IC50s of 1.68 and 0.495 nM, respectively. Lurasidone (SM-13496) is also a partial agonist of 5-HT1A receptor with an IC50 of 6.75 nM.

HY-15394S1

(Rac)-Rotigotine-d3 hydrochloride

(Rac)-Rotigotine-d₃ hydrochloride is a deuterium labeled (Rac)-Rotigotine (hydrochloride) (HY-15394). (Rac)-Rotigotine hydrochloride is a racemate of Rotigotine. Rotigotine is a full agonist of?dopamine receptor, a partial agonist of the?5-HT1A receptor, and an antagonist of the?α2B-adrenergic receptor, with?K_is of 0.71?nM, 4-15?nM, and 83?nM for the dopamine D3 receptor and D2, D5, D4 receptors, and dopamine D1 receptor.

HY-126057S

(R)-Praziquantel-d11
(R)-Praziquantel-d₁₁ is the deuterium labeled (R)-Praziquantel. (R)-Praziquantel, the active enantiomer of Praziquantel, is a partial agonist of the human 5-HT2B receptor. (R)-Praziquantel acts as an antischistosomal eutomer[1].

HY-B1658S

Frovatriptan-d3 hydrochloride
Frovatriptan-d₃ (hydrochloride) is the deuterium labeled Frovatriptan[1]. Frovatriptan is a potent 5-HT1B//D receptor agonist and has the highest 5-HT1B potency in the triptan class. Frovatriptan is apparently cerebroselective. Frovatriptan is efficacious and even superior in some endpoints also when taken during the headache phase in migraine attacks with aura[2].

HY-133152S

Brexpiprazole S-oxide-d8

Brexpiprazole S-oxide-d₈ is a deuterium labeled Brexpiprazole S-oxide. Brexpiprazole S-oxide is a main metabolite of Brexpiprazole and is metabolized by cytochrome P450 3A4 (CYP3A4). Brexpiprazole is an atypical antipsychotic agent and a partial agonist of human 5-HT1A and dopamine receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM[1][2][3].

HY-15296S1

Cabergoline-d6
Cabergoline-d₆ is deuterium labeled Cabergoline. Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively).

HY-A0039S1

Eletriptan-d5
Eletriptan-d₅ is the deuterium labeled Eletriptan[1]. Eletriptan (UK-116044) is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan can be used for researching migraine[2].

HY-15296S

Cabergoline-d5
Cabergoline-d₅ is the deuterium labeled Cabergoline. Cabergoline is an ergot derived-dopamine D2-like receptor agonist that has high affinity for D2, D3, and 5-HT2B receptors (Ki=0.7, 1.5, and 1.2, respectively)[1][2].

HY-14546S1

Aripiprazole (1,1,2,2,3,3,4,4-d8) 5+ Cited Publications
Aripiprazole (1,1,2,2,3,3,4,4-d₈) is the deuterium labeled Aripiprazole. Aripiprazole (OPC-14597) is a human 5-HT1A receptor partial agonist with a Ki of 4.2 nM[1][2].

HY-17038S1

Agomelatine-d4
Agomelatine-d₄ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

HY-17038S2

Agomelatin-d3
Agomelatin-d₃ is the deuterium labeled Agomelatine. Agomelatine (S-20098) is a specific agonist of MT1 and MT2 receptors with Kis of 0.1, 0.06, 0.12, and 0.27 nM for CHO-hMT1, HEK-hMT1, CHO-hMT2, and HEK-hMT2, respectively[1]. Agomelatine is a selective 5-HT2C receptor antagonist with pKis of 6.4 and 6.2 at native (porcine) and cloned, human 5-HT2C receptors, respectively[2].

HY-15780S1

Brexpiprazole-d8-1

Brexpiprazole-d₈-1 is the deuterium labeled Brexpiprazole[1]. Brexpiprazole (OPC-34712), an atypical orally active antipsychotic agent, is a partial agonist of human 5-HT1A and dopamine D2L receptor with Kis of 0.12 nM and 0.3 nM, respectively. Brexpiprazole is also a 5-HT2A receptor antagonist with a Ki of 0.47 nM. Brexpiprazole also shows potent antagonist activity at human noradrenergic α1B (Ki=0.17 nM) and α2C receptors (Ki=0.59 nM)[2][3].

HY-A0039S2

Eletriptan-d5 hydrochloride

Eletriptan-d₅ (hydrochloride) is the deuterium labeled Eletriptan hydrochloride[1]. Eletriptan (UK-116044) hydrochloride is a highly selective and orally active serotonin 5-HT1B and 5-HT1D receptor agonist, with pKi values of 8.0 and 8.9, respectively. Eletriptan hydrochloride has inhibitory effects on markers of neurogenic inflammation in rats. Eletriptan hydrochloride can be used for researching migraine[2].

HY-B0982S

Pindolol-d7
Pindolol-d₇ (LB-46-d7) is the deuterium labeled Pindolol. Pindolol (LB-46) is a nonselective β-blocker with partial beta-adrenergic receptor agonist activity, also functions as a 5-HT1A receptor weak partial antagonist (Ki=33 nM)[1][2].

HY-14262S1

Vilazodone-d8 hydrochloride
Vilazodone-d₈ hydrochloride is deuterated labeled Vilazodone (HY-14262). Vilazodone (EMD 68843; SB 659746A) is a potent, selective and orally active?serotonin?reuptake inhibitor (SSRI) and partial?5-HT₁A *receptor* agonist. Vilazodone exhibits antidepressant efficacy in vivo can be used for the research of major depressive disorder (MDD) and affective disorders .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks